Genitourinary cancers affect the urinary organs of men and women, including the bladder, kidney, urethra and ureter, as well as the major organs of the reproductive system in men, including the prostate, penis and testes.
UMass Memorial Health Care has a multidisciplinary team—including medical and surgical oncologists, radiation oncologists, radiologists and pathologists—who are dedicated to the expert diagnosis and superb personal care of patients with genitourinary cancers. They are committed to providing exceptional clinical care to patients and offer a combination of treatment options, including minimally invasive and robotic surgery, chemotherapy and radiation therapy.
Learn more about the care services and resources offered for patients with genitourinary cancer at UMass Memorial Health Care.
Researchers at UMass Cancer Center seek to understand how genitourinary cancers begin and can be treated. The Department of Urology, the only academic urology department in Central and Western Massachusetts, is committed to improving the understanding of urologic disease through research and discovery and developing treatment paradigms that maximize optimal outcomes while minimizing the invasiveness and cost of these therapies.
We are a Main Member institution of the ECOG-ACRIN Cancer Research Group, a cooperative membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. As an ECOG-ACRIN member, we are able to provide patients with access to colorectal cancer clinical trials being conducted through the National Clinical Trials Network. Our surgical team participates in several national and international trials regarding surgical treatment of genitourinary cancer to be sure we are always able to provide the most advanced available options for our patients.
Seeking people aged 30 and younger newly diagnosed with diffuse anaplastic Wilms tumor, a type of cancer that occurs in the kidney, for a study of experimental treatment regimen because no standard treatment regimen currently exists.
Seeking Male & Female patients age 0-30 years who have a kidney tumor (an abnormal growth of cells or tissues in the kidney that may be benign or malignant) or a tumor outside the kidney called a malignant rhabdoid tumor or an extrarenal Wilms tumor.
Seeking men and women whose high-risk, non-muscle invasive bladder cancer has not spread to the muscle for a study comparing the standard Bacillus Calmette-Guerin (BCG) immunotherapy to an investigational chemotherapy drug combination.
Seeking people aged 12 and older whose previous treatment has failed for a study of an investigational drug for locally advanced or metastatic cancer of the bladder, urinary tract, and other solid tumors
Seeking men and women aged 18 and older who have upper tract urothelial cancer for a study of whether adding an immunotherapy drug to the standard chemotherapy aid in preventing or delaying the cancer from growing.
Seeing men and women whose renal cell cancer has spread to their bones for a study of an investigational drug combination to reduce pain.
IRONMAN Registry aims to collect detailed information about the participants in the study at the time of enrollment and to follow their medical care to better understand what treatments work and where there are unmet needs in their treatment.
Volunteers with advanced prostate cancer that has spread to their bones sought for a study of an investigational drug to assess if it stops the cancer from growing
